Survival Outcome of Tyrosine Kinase Inhibitors Beyond Progression in Association to Radiotherapy in Oligoprogressive EGFR-Mutant Non-Small-Cell Lung Cancer

References

• Rosell R , CarcerenyE, GervaisRet al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase III trial. Lancet Oncol.13(3), 239–246 (2012).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL, ThongprasertSet al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.361, 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T , MoritaS, YatabeYet al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase III trial. Lancet Oncol.11, 121 (2010).
   PubMed Web of Science ®Google Scholar
• Sequist LV , YangJC, YamamotoNet al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol.31(27), 3327–3334 (2013).
   PubMed Web of Science ®Google Scholar
• Kuiper JL , HeidemanDA, ThunnissenEet al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer.85, 19–24 (2014).
   PubMed Web of Science ®Google Scholar
• Goss G , TsaiC-M, ShepherdFAet al. Osimertinib for pretreated EGFR Thr790 Met-positive advanced non-small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, Phase II study. Lancet Oncol.17, 1643–1652 (2016).
   PubMed Web of Science ®Google Scholar
• Nishie K , KawaguchiT, TamiyaAet al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J. Thorac. Oncol.7, 1722–1727 (2012).
   PubMed Web of Science ®Google Scholar
• Lo PC , DahlbergSE, NishinoMet al. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer121, 2570–2577 (2015).
   PubMed Web of Science ®Google Scholar
• Park K , YuCJ, KimSWet al. First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian Patients With epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study. JAMA Oncol.2(3), 305–312 (2016).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur. J. Cancer45, 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Toxicity and response criteria of the Eastern Cooperative Oncology group . Am. J. Clin. Oncol. 19382, 5(6), 649–655https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdf
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ , ScheierB, BurkeJMet al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene addicted non-small cell lung cancer. J. Thorac. Oncol.7(12), 1807–1814 (2012).
   PubMed Web of Science ®Google Scholar
• Yu HA , SimaCS, HuangJet al. Local therapy withcontinued EGFR tyrosine kinase inhibitor therapy as a treatment strategy inEGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J. Thorac. Oncol.8, 346–351 (2013).
   PubMed Web of Science ®Google Scholar
• Yoshida T , YohK, NihoSet al. RECIST progression patterns during EGFR tyrosine kinase inhibitortreatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Lung Cancer90, 477–483 (2015).
   PubMed Web of Science ®Google Scholar
• Chaft JE , OxnardGR, SimaCSet al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutantlung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin. Cancer Res.17, 6298–6303 (2011).
   PubMed Web of Science ®Google Scholar
• Park K , YuCJ, KimSWet al. First-line erlotinibtherapy until and beyond response evaluation criteria in solid tumorsprogression in asian patients with epidermal growth factor receptormutation-positive non-small-cell lung cancer: the ASPIRATION study. JAMA Oncol.2, 305–312 (2016).
   PubMed Web of Science ®Google Scholar
• Oxnard GR , LoP, JackmanDMet al. Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer. J. Clin. Oncol.30(Suppl.15), abstr 7547 (2012).
   Google Scholar
• Faehling M , EckertR, KampTGet al. Treatment with EGFR tyrosine kinase inhibitors beyond progression in long-term responders to erlotinib in advanced non-small cell lung cancer: a case control study of overall survival. Lung Cancer80(3), 306–312 (2013).
   PubMed Web of Science ®Google Scholar
• Novello S , BarlesiF, CalifanoRet al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.27, v1–v27 (2016).
   PubMed Web of Science ®Google Scholar
• Yu HA , SimaCS, HuangJet al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J. Thorac. Oncol.8(3), 346–351 (2013).
   PubMed Web of Science ®Google Scholar
• Shukuya T , TakahashiT, NaitoTet al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer74, 457–461 (2011).
   PubMed Web of Science ®Google Scholar